Provides CyClean technology for pre-combustion coal treatment to reduce nitrogen oxide and mercury emissions. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
No real growth (5% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 0.9× for every dollar of annual revenue.
No analyst target is on record for this company.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades 59% below its peak. The market has trimmed its expectations for the company.
Sales run at $120.3M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 49 buys and 10 sells. Management buying with its own money is usually read as a good sign.
It pays out $1.00 per share each year — regular cash for whoever holds the stock.
A loss of $52.6M against $120.3M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.